Skip to Content
Merck
All Photos(1)

Key Documents

05-517

Sigma-Aldrich

Anti-PTH/PTHrP Receptor Antibody, clone 3D1.1

clone 3D1.1, Upstate®, from mouse

Synonym(s):

Anti-BDE2, Anti-HHM, Anti-PLP, Anti-PTHR, Anti-PTHRP

Sign Into View Organizational & Contract Pricing

Select a Size

All Photos(1)

Select a Size

Change View

About This Item

UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41

biological source

mouse

Quality Level

100

antibody form

purified immunoglobulin

antibody product type

primary antibodies

clone

3D1.1, monoclonal

species reactivity

pig, human, mouse

manufacturer/tradename

Upstate®

technique(s)

immunohistochemistry: suitable
western blot: suitable

isotype

IgG1κ

NCBI accession no.

NM_000315

Specificity

Recognizes PTH/PTHrP receptor and the receptor dimer.

Immunogen

Synthetic peptide corresponding to amino acids 146-169 of the human PTH/PTHrP (parathyroid hormone/parathyroid hormone related protein) receptor (RRCDRNGSWELVPGHNRTWANYSE).

Application

Anti-PTH/PTHrP Receptor Antibody, clone 3D1.1 is an antibody against PTH/PTHrP Receptor for use in IH & WB.
Research Category
Neuroscience
Research Sub Category
Hormones & Receptors

Quality

Routinely evaluated by immunoblot on RIPA lysates of 3T3-L1 pre-adipose fibroblasts

Target description

80 kDa; receptor dimer at 160 kDa

Physical form

Format: Purified
Protein G Purified
Protein G Purified immunoglobulin in Immunoaffinity Purified immunoglobulin in 0.2M Tris-glycine, pH 7.4, 0.15M NaCl, 0.05% sodium azide before the addition of glycerol to 30%

Storage and Stability

Maintain for 2 years at -20°C from date of shipment. Aliquot to avoid repeated freezing and thawing. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

Analysis Note

Control
Kidney Tissue

Other Notes

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Legal Information

UPSTATE is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Not finding the right product?  

Try our Product Selector Tool.

Storage Class Code

10 - Combustible liquids

WGK

WGK 1

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Christine V Marzan et al.
Developmental biology, 349(2), 125-136 (2010-10-27)
We generated a transgenic (Tg)-mouse model expressing a dominant negative-(DN)-RARα, (RARαG303E) under adipocytes-specific promoter to explore the paracrine role of adipocyte retinoic acid receptors (RARs) in mammary morphogenesis. Transgenic adipocytes had reduced level of RARα, β and γ, which coincided
Cell-specific effects of nitric oxide deficiency on parathyroid hormone-related peptide (PTHrP) responsiveness and PTH1 receptor expression in cardiovascular cells.
Rolf Schreckenberg, Sibylle Wenzel, Rui Manuel da Costa Rebelo, Anja Rothig, Rainer Meyer et al.
Endocrinology null
Altered ovarian function affects skeletal homeostasis independent of the action of follicle-stimulating hormone.
Gao, J; Tiwari-Pandey, R; Samadfam, R; Yang, Y; Miao, D; Karaplis, AC; Sairam, MR; Goltzman, D
Endocrinology null
Nathalie Alekos et al.
JCI insight (2023-02-03)
The energetic costs of bone formation require osteoblasts to coordinate their activities with tissues, like adipose, that can supply energy-dense macronutrients. In the case of intermittent parathyroid hormone treatment (PTH), a strategy used to reduce fracture risk, bone formation is
Kimberly J Curtis et al.
Journal of the Royal Society, Interface, 17(173), 20200568-20200568 (2020-12-17)
Most patients who succumb to cancer have metastases to bone that contribute to their death. Cancer cells that metastasize to bone are regularly subjected to mechanical stimuli that may affect their proliferation, growth and protein expression. Understanding why some cancer
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service